First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study. Shah R, Buchmeier EL, Kopp HG, Christoph DC, et al. Lung Cancer 2025;207:108702.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shah R, Buchmeier EL, Kopp HG, Christoph DC, et al. First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study. Lung Cancer 2025;207:108702.
PMID: 40779889